Hoffmann-la Roche

This study tests a new drug, RO7771950, designed to reach the brain, for people with HER2-positive breast cancer that has spread to the brain or other organs. About 650 participants will receive either the new drug or an existing drug (tucatinib), both combined with standard ther…

This study tests a drug called afimkibart in 100 children aged 2 to 17 with moderate-to-severe Crohn's disease. The goal is to see if it can help children feel better and heal their gut lining. Participants will receive the drug as an IV or injection, and doctors will monitor the…

This Phase 3 trial tests satralizumab, a drug that calms the immune system, in 120 people with two types of autoimmune encephalitis (NMDAR or LGI1). The goal is to see if it improves disability and reduces the need for emergency treatments. Participants receive injections every 4…

This Phase 3 trial tests whether trontinemab can slow down Alzheimer's in people with early symptoms like mild memory problems. About 800 volunteers will receive either the drug or a placebo by IV for 72 weeks. The study measures changes in thinking, daily function, and safety.

This early-stage trial is testing whether combining two existing immunotherapy drugs (mosunetuzumab or glofitamab) with newer oral drugs (iberdomide and/or golcadomide) can safely treat B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. About 121 a…

This early-stage trial tests an experimental daily pill called RO7795081 in 30 healthy Chinese adults who are overweight or obese. The main goal is to check the drug's safety and how the body handles it, not yet to prove weight loss. Participants will receive either the drug or a…

This study tests whether adding risdiplam, a daily oral medicine, can help children under 2 with spinal muscular atrophy (SMA) who stopped getting better or started declining after receiving gene therapy. The study will enroll 28 children and measure changes in motor skills over …

This phase 3 trial tests whether adding the targeted therapy inavolisib to the standard maintenance treatment Phesgo can help people with a specific genetic mutation (PIK3CA) and HER2-positive advanced breast cancer live longer without their cancer growing. About 230 participants…

This phase 3 study tests a drug called afimkibart in 600 people with moderate-to-severe Crohn's disease. Participants receive either the drug or a placebo to see if it can reduce symptoms and gut inflammation. The trial is double-blind, meaning neither patients nor doctors know w…

This early-stage study tests a new drug called RO7663498, given as an injection into the eye, in 30 people with diabetic retinopathy. The main goal is to check safety and how the drug moves through the body. Researchers will watch for side effects and measure drug levels in the e…

This early-stage trial is testing a gene therapy called SPK-8011QQ in 5 adult men with severe or moderately severe hemophilia A. The main goal is to see if the treatment is safe and tolerable. Participants receive a one-time IV infusion of the therapy, and researchers will monito…

This Phase 3 trial tests whether the drug trontinemab can slow the progression of early Alzheimer's disease. About 800 people with mild cognitive impairment or mild dementia due to Alzheimer's will receive either the drug or a placebo intravenously. The study will measure changes…

This study tests a drug called satralizumab in children aged 2 to 11 who have a rare autoimmune disease called NMOSD. The main goal is to see how the drug moves through the body and if it can safely reduce relapses. Only 8 children will take part, and the results will help doctor…

This study tests a new gene therapy called SPK-10001 for people with Huntington's disease. It involves a one-time infusion into specific areas of the brain. The main goal is to see if it is safe and if it can slow down the worsening of movement and daily function. About 53 adults…

This study tests an experimental drug called prasinezumab in 900 people with early-stage Parkinson's disease who are already taking levodopa. The goal is to see if the drug can delay worsening of motor symptoms compared to a placebo. Participants receive the drug or placebo by IV…

This study is checking the long-term safety of a small implant placed in the eye that slowly releases medicine to treat wet age-related macular degeneration, a condition that can cause rapid vision loss. About 1,000 people who have already used the implant in earlier studies will…

This study tests a medicine called emicizumab to prevent bleeding episodes in people with Type 3 von Willebrand disease, a severe inherited bleeding disorder. About 75 participants, from infants to adults, will receive either emicizumab or continue their current treatment. The go…

This study tests a new medicine called sefaxersen for people with IgA nephropathy, a kidney disease that can lead to kidney failure. The drug aims to reduce protein in the urine and slow kidney damage. About 428 adults who are at high risk of worsening kidney disease will receive…

This study tests whether adding the experimental drug cevostamab to standard medications (pomalidomide and dexamethasone) works better than current treatments for multiple myeloma. About 380 adults whose cancer came back after 1 to 3 prior therapies will take part. The goal is to…

This study compares a new drug called glofitamab against standard treatments (rituximab plus bendamustine or lenalidomide plus rituximab) in about 182 adults with mantle cell lymphoma that has returned or not responded to prior therapy. Participants must have tried at least one p…

This study tests a new drug called glofitamab, alone or with standard chemotherapy, in children and young adults (ages 6 months to under 30) whose B-cell lymphoma has come back or not responded to treatment. The goal is to see if the drug is safe and can shrink or control the can…

This study tests a new medicine called afimkibart in children aged 2 to 17 with moderate to severe ulcerative colitis, a disease that causes inflammation and sores in the colon. The goal is to see if the drug can safely help children feel better and achieve remission (no symptoms…

This study compares two versions of the multiple sclerosis drug ocrelizumab given as a shot under the skin. About 182 adults with relapsing or primary progressive MS will receive one dose of either the test or the marketed version, then all will continue with the test version. Th…

This phase 2 trial tests whether adding a personalized cancer vaccine (autogene cevumeran) to the immunotherapy nivolumab can prevent high-risk bladder cancer from coming back after surgery. About 62 participants will receive either the combination or nivolumab alone. The study o…

This study is observing how well the drug glofitamab works and how safe it is for Chinese adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have already tried one prior treatment. Researchers will track 300 participants receiving glofitamab as part of t…

This study is testing whether the drug risdiplam can improve motor skills in children under 2 with spinal muscular atrophy (SMA) who have already received gene therapy. The 28 participants will take risdiplam by mouth, and researchers will measure changes in their gross motor ski…

This study tests a small, refillable implant placed in the eye that slowly releases medication for wet age-related macular degeneration (nAMD). It aims to see if refilling the implant every 24 weeks works as well as getting a standard eye injection every 4 weeks. About 68 Chinese…

This Phase 3 trial tests a new drug called NXT007 (Zemocimig) against standard Factor VIII treatment to prevent bleeding in people with severe or moderate hemophilia A who do not have inhibitors. About 126 participants aged 12 and older will receive either NXT007 as a shot under …

This Phase 3 study compares a new daily pill, giredestrant, against the standard shot fulvestrant, both given alongside a CDK4/6 inhibitor, in about 1,050 people with ER+/HER2- advanced breast cancer that has become resistant to prior hormone therapy. The goal is to see if girede…

This phase 2 trial is testing whether adding a drug called inavolisib to two standard treatments (ribociclib and fulvestrant) can shrink tumors or slow cancer growth in people with advanced hormone-receptor-positive, HER2-negative breast cancer that has a specific genetic change …

This study looks at how well the flu drug baloxavir marboxil works in children under 12 and whether it stops the flu from spreading to family members. About 1,100 kids with flu symptoms will take the drug, and researchers will check for drug resistance and track infections in hou…

This study tests alectinib, a targeted cancer drug, in children and teens with ALK fusion-positive solid or central nervous system (CNS) tumors that have not responded to other treatments or have no standard therapy. About 42 participants will take alectinib capsules twice daily …

This early-stage study tests a new drug called RG6496 in people who carry the gene for Huntington's disease. The main goal is to check if the drug is safe and how the body handles it. About 40 participants will receive a single dose injected into the spine, with some getting a pl…

This early-stage study tests an experimental drug called cevostamab in about 20 Chinese adults whose multiple myeloma has returned or stopped responding to standard treatments. The main goals are to check the drug's safety, how the body processes it, and whether it can shrink tum…

This study tests a new medicine called NXT007 for people with severe or moderate hemophilia A, a bleeding disorder. The trial includes adults, teenagers, and children, both with and without inhibitors that make standard treatment less effective. Researchers will check if the drug…

This study tests whether adding the drug inavolisib to standard hormone therapy and a CDK4/6 inhibitor can help people with a specific type of advanced breast cancer (PIK3CA-mutated, HR+, HER2-). About 450 adults whose cancer has not been treated yet in the advanced setting will …

This study tests the safety and effectiveness of targeted therapies or immunotherapies in people with metastatic colorectal cancer (cancer that has spread). Participants are assigned to a treatment based on specific biomarkers found in their tumor. The goal is to see if these per…

This study is for people with advanced ER-positive breast cancer that has stopped responding to standard treatments. It tests several new drug combinations to see which ones work best and are safe. About 316 participants will be assigned to different treatment groups based on the…

This early-phase study tests a new drug, RO7673396, in people with advanced solid tumors that have a RAS mutation. The goal is to find a safe dose and see if the drug can shrink tumors, either alone or with other cancer treatments. About 405 adults with incurable cancers will tak…

This study looks at how well the drug inavolisib works for people with a certain type of advanced breast cancer that has a PIK3CA gene change and has stopped responding to hormone therapy. About 500 participants in China will receive inavolisib as part of their regular care. Rese…

This study compares a new drug, NXT007, to an existing one (emicizumab) for preventing bleeding episodes in people aged 12 and older with hemophilia A. Participants may have severe, moderate, or mild disease, with or without factor VIII inhibitors. The goal is to see if NXT007 is…

This early-phase study tests a new drug (glofitamab) combined with two chemotherapy drugs (gemcitabine and oxaliplatin) in about 50 U.S. adults whose diffuse large B-cell lymphoma has returned or stopped responding to prior treatment. The main goals are to check safety and see ho…

This early-stage study is testing a new treatment for people with metastatic colorectal cancer that has stopped responding to standard therapies. The treatment uses a two-step process to deliver a radioactive particle directly to cancer cells, aiming to control the disease. About…

This study follows 800 adults in China who had surgery for early-stage ALK-positive non-small-cell lung cancer and then took alectinib to prevent the cancer from coming back. Researchers will track how long patients stay cancer-free in real-world settings. The goal is to see how …

This study looks at the long-term safety of the drug astegolimab in people with chronic obstructive pulmonary disease (COPD). It includes about 2,000 participants who already completed a one-year study with the drug. The main goal is to track any side effects that may occur with …

This study tests if obinutuzumab can help teens and children with lupus nephritis, a serious kidney complication of lupus. About 40 participants aged 5 to 17 will receive either the drug or a placebo. The goal is to see if the drug improves kidney function and reduces protein in …

This study tests two different doses of inavolisib combined with fulvestrant in people with a specific type of advanced breast cancer (PIK3CA-mutated, HR-positive, HER2-negative). About 80 participants whose cancer worsened after prior treatment will receive the drug combo. The g…

This early-stage study is for people with chronic lymphocytic leukemia (CLL) that has come back or stopped responding to treatment. It tests a drug called mosunetuzumab, either alone or combined with venetoclax, to see if it is safe and can help shrink the cancer. About 137 adult…

This study tests a new once-weekly injection called enicepatide for weight loss in 1600 adults who have obesity or overweight and type 2 diabetes. The drug works by mimicking natural hormones to help control appetite and blood sugar. Participants will receive either the drug or a…

This study gives people with cancer continued access to an experimental Roche treatment they were already receiving in a previous trial. It is for patients who still need the drug and cannot get it locally. The goal is to keep providing the treatment and monitor any side effects.

This study is testing several new drug combinations for people with multiple myeloma, a type of blood cancer. The trial is open to 200 participants who have already had some treatment. The goal is to see if these combinations are safe and help control the disease. Because multipl…

This study is testing an experimental drug called fenebrutinib in 12 children and teenagers (ages 10 to under 18) with relapsing multiple sclerosis. The goal is to see how the drug works in the body, whether it reduces brain lesions seen on MRI scans, and if it is safe. Participa…

This study tests a new drug called RO7790121 for people with moderate to severe ulcerative colitis, a condition that causes inflammation in the colon. About 350 adults who haven't responded well to other treatments will receive either the drug or a placebo. The main goal is to se…

This study tests a drug called divarasib, either alone or with other cancer treatments, in people with advanced lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the drug is safe and works to shrink or control the cancer. About 320 people who have …

This early-stage study tests a new drug called RO7812653 in 50 people with early Alzheimer's disease. The main goal is to check if the drug is safe and how the body handles it. Participants receive a single dose injected into the spine and are closely monitored for side effects.

This study tests a refillable eye implant that delivers medication every 36 weeks (about twice a year) for people with wet age-related macular degeneration (AMD). The goal is to see if this less frequent treatment schedule keeps vision stable and is safe. About 250 participants w…

This study tests a new drug combination (glofitamab plus gemcitabine and oxaliplatin) in about 100 people with aggressive B-cell lymphoma that has returned or not responded to prior therapy. The main goal is to see if a better steroid plan can reduce a serious side effect called …

This study is testing the drug risdiplam in newborn babies with spinal muscular atrophy (SMA), a serious muscle-weakening disease. The goal is to see how the drug moves through the body and if it is safe for infants under 20 days old. Ten babies will take part, and researchers wi…

This study tests several different drug combinations in people with metastatic or inoperable locally advanced breast cancer. It includes different groups based on breast cancer type and prior treatments. The goal is to see which combinations work best to control the disease and s…

This study tests whether a combination of two drugs (inavolisib plus enzalutamide) works better than standard treatments for men with a certain type of advanced prostate cancer that no longer responds to hormone therapy. About 100 participants will be randomly assigned to receive…

This early-stage study is testing a new drug called RO7121932 in 129 people with multiple sclerosis (MS). The goal is to check if the drug is safe and how the body handles it when given as a single or multiple doses, either through a vein or under the skin. Participants are not o…

This study aims to create a blood test that helps doctors quickly diagnose traumatic brain injury (TBI) and predict how patients will recover. Researchers will also see if the test can detect complications in hospitalized patients. The study will enroll 2000 adults who come to th…

This study observes about 700 people with lung or liver cancer who are already receiving atezolizumab as a shot under the skin. Researchers want to see how satisfied patients are with this treatment and how it affects their quality of life. The study does not test a new drug but …

This study enrolls 600 adults with Huntington disease to examine specific genetic markers (SNPs) linked to the disease. Participants provide a blood sample and answer questions about their health and medications. The goal is to better understand the genetics of Huntington disease…

This study is collecting information from 850 people with wet age-related macular degeneration or diabetic macular edema who are being treated with faricimab (VABYSMO) in routine clinical practice. Researchers will track vision changes, eye thickness, and treatment patterns over …

This study is a large-scale screening program to find people who may be eligible for Roche's Alzheimer's drug trials. It involves a simple blood test and a memory assessment. Up to 13,000 participants with memory concerns will be evaluated. No experimental treatment is given in t…

This study follows 842 people with multiple sclerosis who are starting a new under-the-skin injection of ocrelizumab. Researchers will ask participants how satisfied they are with the injection after 1, 6, and 12 months. The goal is to understand patient experience, not to test t…

This early-stage study is testing an experimental oral drug called RO7795081 in 40 healthy overweight or obese adults. The main goals are to check the drug's safety and see how it affects two common cholesterol-lowering statins (pitavastatin and rosuvastatin). Participants will r…

This study is testing a digital platform that combines brain scan analysis with a patient app and a doctor web portal to monitor relapsing-remitting multiple sclerosis (MS). About 500 participants will use the platform for two years. The goal is to see if doctors and patients fin…

This study is an early-stage trial to check the safety of a new drug called RO7763505. It involves 196 participants, first in healthy volunteers and then in people with stable coronary artery disease. The main goal is to see if the drug is safe and how the body processes it, not …

This study looks at how the location of treatment affects whether people with early-stage HER2-positive breast cancer stick to their therapy plan. Researchers will compare patients who have to travel far for treatment with those who don't. The goal is to see if making treatment m…

This study aims to understand why some breast cancers become resistant to therapy. Researchers will analyze tumor and blood samples from 320 people with HER2-positive, hormone receptor-positive, or triple-negative breast cancer. The goal is to identify changes in cancer cells tha…

This early-stage study is testing a new drug called RO7806881 in healthy volunteers to see if it is safe and how the body processes it. About 128 healthy adults will receive either the drug or a placebo. The main goal is to check for side effects and measure drug levels in the bl…